The most important question at the FDA Stem Workshop was the one not asked
I didn’t hear the first couple of presentations in the FDA’s Stem Cell workshop. However, I did listen from mid-morning to Dr. Irv Weisman’s closing. Yesterday’s post was my take on the highlights. http://rickjaffeesq.com/2016/09/08/really-tough-day-stem-cell-advocates/ Upon reflection, what is disturbing to me is what I didn’t hear, namely a discussion or even a mention of what I think should have been the most important question in the autologous stem cell public policy debate: whether autologous stem cell transplants should be treated…